<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131053</url>
  </required_header>
  <id_info>
    <org_study_id>JALSG ALL202-U</org_study_id>
    <nct_id>NCT00131053</nct_id>
  </id_info>
  <brief_title>Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)</brief_title>
  <official_title>Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients With BCR-ABL-Negative Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Adult Leukemia Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Japan Adult Leukemia Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety for treating adult ALL
      patients with the pediatric protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prognosis for adult acute lymphoblastic leukemia (ALL) remains poor, which contrasts with
      that for pediatric ALL. It is regarded that the prognostic diversity is attributable to
      several differences between adults and children with respect to biological characteristics of
      leukemic cells, tolerance to anticancer drugs, treatment itself, and so on. It has been
      reported that adolescent ALL patients who were treated according to the pediatric protocol
      had a significantly better survival than those who were treated according to the adult
      protocol, indicating that the difference of treatment may be of considerable importance. To
      test the hypothesis, the Japan Adult Leukemia Study Group (JALSG) has planned a phase 2 study
      to treat younger ALL patients who are negative for BCR-ABL with the pediatric regimen which
      was used by the Japan Association of Childhood Leukemia Study. Those who are positive for
      BCR-ABL can participate in a separate protocol. The regimen is especially characterized by
      dose-intensified L-asparaginase, high-dose methotrexate, and intensified maintenance therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2002</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of complete remission</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lymphoblastic Leukemia, Acute</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirarubicin</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-asparaginase</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated BCR-ABL-negative ALL

          -  Age between 15 and 24 years

          -  Performance status between 0 and 3 (ECOG criteria)

          -  Adequate functioning of the liver (serum bilirubin level &lt; 2.0 mg/dL); kidneys (serum
             creatinine level &lt; 2.0 mg/dL); and heart (left ventricular ejection fraction greater
             than 50% and no severe abnormalities detected on electrocardiograms and
             echocardiographs).

          -  Written informed consent to participate in the trial

        Exclusion Criteria:

          -  Uncontrolled active infection

          -  Another severe and/or life-threatening disease

          -  Positive for HIV antibody and/or hepatitis B surface (HBs) antigen tests

          -  Another primary malignancy which is clinically active and/or requires medical
             interventions

          -  Pregnant and/or lactating women

          -  Past history of renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fumihiko Hayakawa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nagoya University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tomoki Naoe, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nagoya University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fumihiko Hayakawa, MD</last_name>
    <email>bun-hy@med.nagoya-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology, Nagoya University Graduate School of Medicine</name>
      <address>
        <city>Nagoya</city>
        <zip>466-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fumihiko Hayakawa, MD</last_name>
      <email>bun-hy@med.nagoya-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Fumihiko Hayakawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jalsg.jp/</url>
    <description>The JALSG homepage</description>
  </link>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2005</study_first_submitted>
  <study_first_submitted_qc>August 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2005</study_first_posted>
  <last_update_submitted>November 13, 2008</last_update_submitted>
  <last_update_submitted_qc>November 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2008</last_update_posted>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>newly diagnosed</keyword>
  <keyword>BCR-ABL-negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Pirarubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

